The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

OBJECTIVE Patients with schizophrenia frequently present with negative symptoms and cognitive impairments for which no effective treatments are known. Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments. METHOD The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was a 16-week double-blind, double-dummy, parallel group, randomized clinical trial of adjunctive glycine, D-cycloserine, or placebo conducted at four sites in the United States and one site in Israel. The participants were 157 inpatients and outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospective criteria for moderate to severe negative symptoms without marked positive, depressive, or extrapyramidal symptoms. The primary outcome measures were the average "rate of change" of Scale for the Assessment of Negative Symptoms (SANS) total scores and change in the average cognitive domain z scores. RESULTS There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects. A prespecified test for the site-by-treatment-by-time interaction was significant in post hoc tests. One site had greater reduction in the SANS total score for patients receiving D-cycloserine relative to patients receiving placebo. A second site had greater reduction in the SANS total score for placebo patients compared with glycine patients. There were no significant differences between glycine and placebo or D-cycloserine and placebo subjects on the average cognition z score. CONCLUSIONS The study results suggest that neither glycine nor D-cycloserine is a generally effective therapeutic option for treating negative symptoms or cognitive impairments.

[1]  Yue-Cune Chang,et al.  Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia , 2006, Biological Psychiatry.

[2]  Brian Kirkpatrick,et al.  The NIMH-MATRICS consensus statement on negative symptoms. , 2006, Schizophrenia bulletin.

[3]  D. Javitt.  Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients , 2006, Current opinion in psychiatry.

[4]  Yue-Cune Chang,et al.  D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia , 2006, Biological Psychiatry.

[5]  陳柏維,et al.  Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia , 2005 .

[6]  D. Goff,et al.  A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.

[7]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[8]  R. Conley,et al.  More powerful two‐sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk , 2005, Statistics in medicine.

[9]  J. Tiihonen,et al.  Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis , 2005, Schizophrenia Research.

[10]  J. Corwin,et al.  Effects of d-cycloserine on negative symptoms in schizophrenia , 2004, Schizophrenia Research.

[11]  Nicholas Lange,et al.  Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia , 2004, Biological Psychiatry.

[12]  Shan Xie,et al.  Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists , 2004, Neuropsychopharmacology.

[13]  D. Javitt,et al.  High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia , 2004, Biological Psychiatry.

[14]  J. Coyle,et al.  Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.

[15]  D. Javitt,et al.  Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, International Journal of Neuropsychopharmacology.

[16]  R. Buchanan,et al.  Assessing the Efficacy of Treatments for the Deficit Syndrome of Schizophrenia , 2000, Neuropsychopharmacology.

[17]  J. Coyle,et al.  D-serine added to clozapine for the treatment of schizophrenia. , 1999, The American journal of psychiatry.

[18]  Russell D. Wolfinger,et al.  Multiple Comparisons and Multiple Tests Using the SAS System , 1999 .

[19]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[20]  Peter H. Westfall,et al.  Multiple Testing of General Contrasts Using Logical Constraints and Correlations , 1997 .

[21]  H. Westenberg,et al.  Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients , 1996, Biological Psychiatry.

[22]  J. Coyle,et al.  D-cycloserine added to clozapine for patients with schizophrenia. , 1996, The American journal of psychiatry.

[23]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[24]  R. Davis,et al.  D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. , 1996, Clinical neuropharmacology.

[25]  R. Buchanan,et al.  Negative symptoms: diagnosis, treatment and prognosis , 1996, International clinical psychopharmacology.

[26]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[27]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[28]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[29]  J. Coyle,et al.  Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. , 1995, The American journal of psychiatry.

[30]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[31]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[32]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[33]  S. Potkin,et al.  An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. , 1990, Journal of clinical psychopharmacology.

[34]  Robert W. Buchanan,et al.  The schedule for the deficit syndrome: An instrument for research in schizophrenia , 1989, Psychiatry Research.

[35]  S. Deutsch,et al.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. , 1989, Clinical neuropharmacology.

[36]  N C Andreasen,et al.  Negative symptoms in schizophrenia , 1982 .

[37]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[38]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[39]  C. Bakker,et al.  Observations on the psychotomimetic effects of Sernyl. , 1961, Comprehensive psychiatry.

[40]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[41]  Michael F. Green,et al.  Learning potential and the prediction of work skill acquisition in schizophrenia. , 2005, Schizophrenia bulletin.

[42]  Philip D. Harvey,et al.  Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. , 2005, Schizophrenia bulletin.

[43]  K. Greenwood,et al.  Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. , 2005, Schizophrenia bulletin.

[44]  E. Smeraldi,et al.  d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study , 2005, Journal of Neural Transmission / General Section JNT.

[45]  R. Gur,et al.  Symptoms Versus Neurocognitive Test Performance as Predictors of Psychosocial Status in Schizophrenia: A 1- and 4-Year Prospective Study , 2005 .

[46]  J. Kane,et al.  Optimizing pharmacologic treatment of psychotic disorders , 2003 .

[47]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.

[48]  J. Coyle,et al.  A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.